Circulating Tumor Cells and γH2AX As Biomarkers for Responsiveness to radium-223 in Advanced Prostate Cancer Patients | Zendy

Jonathan Alexander Chatzkel | Zendy; Jesse Mocha | Zendy; J. Joshua Smith | Zendy; Junmin Zhou | Zendy; Youngchul Kim | Zendy; Ghassan ElHaddad | Zendy; Jingsong Zhang | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Circulating Tumor Cells and γH2AX As Biomarkers for Responsiveness to radium-223 in Advanced Prostate Cancer Patients

Author(s) -

Jonathan Alexander Chatzkel,

Jesse Mocha,

J. Joshua Smith,

Junmin Zhou,

Youngchul Kim,

Ghassan ElHaddad,

Jingsong Zhang

Publication year - 2019

Publication title -

future science oa

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.825

H-Index - 23

ISSN - 2056-5623

DOI - 10.2144/fsoa-2019-0092

Subject(s) - radium 223 , prostate cancer , medicine , oncology , cancer , biomarker , circulating tumor cell , liquid biopsy , overall survival , urology , cancer research , metastasis , bone metastasis , biology , biochemistry

Aim: Radium-223 improves overall survival in patients with metastatic castration-resistant prostate cancer to the bone. Radium-223 causes double-strand DNA breaks and produces γH2AX, a potential biomarker for response. We examined the feasibility of tracking γH2AX positivity and numeration in circulating tumor cells. Patients & methods: Ten patients with biopsy-confirmed symptomatic M1b castration-resistant prostate cancer received radium-223 as standard of care and were assessed for γH2AX level changes following doses 1, 3 and 6. Results: Trend tests confirmed that patients with ≥50% increase in circulating tumor cells positive for γH2AX postradium-223 therapy had a lower risk of death (p = 0.035). Conclusion: Regular interval measurements of γH2AX are feasible. The potential correlation between γH2AX changes and overall survival warrants further investigation.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research